Loading stock data…
VivoSim Labs (VIVS)
$0.42-0.03 (-6.91%)
Market ClosedLast close Jul 24
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
VivoSim Labs, Inc. in the Healthcare sector is trading at $0.42 with a market capitalization of $3M. The stock is currently near its 52-week low of $0.41, remaining 76.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 17) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $40,000↑ | $26,000↓ | $28,000↓ | $37,000↓ | $51,000 |
| Gross Profit | $40,000↑ | $26,000↓ | $28,000↓ | $37,000↓ | $51,000 |
| Operating Income | -$3.19M↓ | -$2.75M↓ | -$2.63M↑ | -$2.92M↑ | -$3.15M |
| Net Income | -$5.76M↓ | -$2.69M↓ | -$2.54M↑ | -$2.84M↓ | $6.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.63%
Volume
Today's trading volume
1.28M
Recent News
VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)
The company’s initial commercial programs in mainland China expand its geographic reach and mark a new step in the global rollout of its human tissue-based drug testing platform. Key Investor TakeawaysVivoSim (NASDAQ:VIVS) secured its first commercial sales in mainland China through two paid customer engagements.
VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth
The milestone payment strengthens VivoSim’s cash position while management projects significant revenue growth driven by expanding demand for its human-based preclinical testing platform. Key Investor TakeawaysVivoSim (NASDAQ:VIVS) received a $5 million milestone payment from Eli Lilly tied to the advancement of a previously sold drug candidate into Phase 2 studies.
NIO January Deliveries Nearly Double Year On Year
EV maker opens 2026 with strong momentum
Top Midday Gainers
VivoSim Labs (VIVS) said late Thursday it signed agreements appointing JCBio as its distributor in S
BC-Most Active Stocks
GCL Global Holdings Ltd. 49,480,730 1.29